
SNN Stock Forecast & Price Target
SNN Analyst Ratings
Bulls say
Smith & Nephew experienced underlying revenue growth of 5.3%, with significant contributions from its orthopedic and sports medicine segments, showcasing a robust demand particularly in the US market. The company anticipates stronger performance in the second half of the year, underpinned by operational improvements and increased adoption of its advanced technologies, such as the CORI system, which has reached over 1,000 placements. Projections for 2025 indicate continued growth, with guidance of 5% growth and a trading profit margin expected between 19.0% and 20.0%, reinforcing a positive outlook for the firm's financial performance.
Bears say
Smith & Nephew is projecting a weaker financial performance in FY25, particularly in Q1, influenced by a combination of fewer selling days, ongoing inventory challenges in China, and the impacts of evolving reimbursement rates in the US healthcare system. The company's return on invested capital (ROIC) for its orthopedic segment remains significantly below that of its sports medicine and advanced wound management counterparts, highlighting operational inefficiencies within its largest revenue-generating segment. Additionally, persistent headwinds in China and broader market risks tied to political stability and regulatory changes could further exacerbate revenue challenges, contributing to a negative outlook.
This aggregate rating is based on analysts' research of Smith & Nephew and is not a guaranteed prediction by Public.com or investment advice.
SNN Analyst Forecast & Price Prediction
Start investing in SNN
Order type
Buy in
Order amount
Est. shares
0 shares